Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Docetaxel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TACR2 | P21452 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | GHRHR | Q02643 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Docetaxel Anhydrous SCHEMBL121908 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL14060916 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL189598 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL121909 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL301510 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL301509 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL7109515 | 0.99 | TUBB4A (0.99) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL7109517 | 0.99 | TUBB4A (0.99) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL25052982 | 0.99 | NPC1 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL22667521 | 0.99 | NPC1 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681478-B1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT | ATOSSA THERAPEUTICS INC (US) | 2025-09-10 | — | — | EP | claimed |
| CN-115400115-B | Combination and use of docetaxel albumin composition and immune checkpoint inhibitor | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-14 | — | — | CN | claimed |
| CN-118903027-A | Stable docetaxel Albumin nanoparticle compositions | 石药集团中奇制药技术（石家庄）有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-115025053-B | Stable docetaxel Albumin nanoparticle compositions | 石药集团中奇制药技术（石家庄）有限公司 | 2024-08-30 | — | — | CN | claimed |
| EP-3664823-B1 | COMPOSITION FOR USE IN PREVENTING OR TREATING AN ENTEROCOCCAL BLOOD STREAM INFECTION | FINCH THERAPEUTICS HOLDINGS LLC (US) | 2024-06-05 | — | — | EP | claimed |
| US-20240156774-A1 | STABLE DOCETAXEL ALBUMIN NANOPARTICLE COMPOSITION | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2024-05-16 | — | — | US | claimed |
| EP-4302754-A1 | STABLE DOCETAXEL ALBUMIN NANOPARTICLE COMPOSITION | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2024-01-10 | — | — | EP | claimed |
| CN-115025053-A | Stable docetaxel albumin nanoparticle composition | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-09 | — | — | CN | claimed |
| WO-2022184164-A1 | STABLE DOCETAXEL ALBUMIN NANOPARTICLE COMPOSITION | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-09 | — | — | WO | claimed |
| CN-114259609-A | Support frame | 宇航 | 2022-04-01 | — | — | CN | claimed |
| EP-1819688-A2 | CRYSTALLINE FORMS OF DOCETAXEL AND PROCESSES FOR THEIR PREPARATION | Sicor, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| US-20070142457-A1 | Crystalline forms of docetaxel and processes for their preparation | SICOR, INC. | 2007-06-21 | — | — | US | claimed |
| WO-2007044950-A2 | CRYSTALLINE FORMS OF DOCETAXEL AND PROCESSES FOR THEIR PREPARATION | SICOR, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| CN-1854132-A | Production of polyenoic taxad alcohol trihydrate | AORUITE INTERNAT TRADE CO LTD (CN) | 2006-11-01 | — | — | CN | claimed |
| US-20060217436-A1 | Process for the preparation of docetaxel trihydrate | SHANGHAI DESANO CHEMICAL PHARMACEUTICAL CO., LTD (CN) | 2006-09-28 | — | — | US | claimed |
| CN-1268619-C | Prepn of polyene taxol trihydrate | SHANGHAI DISAINUO CHEMICAL PHA (CN) | 2006-08-09 | — | — | CN | claimed |
| EP-1623982-A1 | THE PROCESS FOR THE PREPARATION OF DOCETAXEL TRIHYDRATE | Shanghai Desano Chemical Pharmaceutical CO., Ltd. (CN) | 2006-02-08 | — | — | EP | claimed |
| US-6838569-B2 | Process for preparation of paclitaxel trihydrate and docetaxel trihydrate | DABUR INDIA LIMITED (IN) | 2005-01-04 | — | — | US | claimed |
| CN-1548426-A | Prepn of polyene taxol trihydrate | �Ϻ�����ŵ��ѧ��ҩ����˾ | 2004-11-24 | — | — | CN | claimed |
| EP-0690852-B1 | METHOD FOR PURIFYING TAXOIDS | RHONE POULENC RORER SA (FR) | 1997-02-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142457-A1 | Crystalline forms of docetaxel and processes for their preparation | RCC1, TBCD, CDC45 | TUBB4A 54/4885TUBB 73/4885TUBA3C 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.